Industry news that matters to you.  Learn more

Archives for January 2017

Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. recently announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab), which may help inform future clinical trials. Additionally, GeneCentric announced it has secured equity funding from Bristol-Myers Squibb that will support the clinical development of GeneCentric’s CSP™ and build-out of GeneCentric’s new laboratory in Research Triangle Park.

Candidate Biomarkers for Postmenopausal Osteoporosis

An article published in Experimental Biology and Medicine (Volume 242, Issue 2, January, 2017) reports a new method for identifying women at risk for osteoporotic fractures. The study, led by Dr. Katre Maasalu, Associate Professor and orthopedic surgeon from Traumatology and Orthopeadic Clinic of Tartu University, demonstrated that a biomarker panel consisting of six genes could distinguish postmenopausal women with osteoporosis, a major risk factor for fracture, from those without osteoporosis.

Serum micoRNAs May Serve as Biomarkers for Multiple Sclerosis

MicroRNAs are small RNA molecules that influence basic cellular processes and have been proposed as biomarkers for the diagnosis, progression and treatment of multiple sclerosis. In a new study conducted at the Ann Romney Center of Neurologic Diseases at Brigham and Women’s Hospital, researchers have found that serum microRNAs are linked to MRI findings in the brain and spinal cord in patients with MS. These findings suggest that microRNAs could serve as promising biomarkers for monitoring the progression of MS and could help to identify distinct underlying disease processes, such as inflammation and tissue destruction.

Biomarker in Pregnant Women Linked to Depression, Low Infant Birth Weight

Depression is very common during pregnancy, with as many as one in seven women suffering from the illness and more than a half million women impacted by postpartum depression in the U.S. alone. The disorder not only affects the mother’s mood, but has also been linked to influencing the newborn’s development, according to recent research.

White Matter Hyperintensity May Serve as Biomarker for SCD, Study Says

An analysis of white matter hyperintensity (WMH, a measure of the risk of stroke) may serve as a biomarker to track the progression of blood vessel anomalies associated with sickle cell disease (SCD) and to check whether treatments were effective, according to new research.

The research study, “Enhanced Long-Term Brain MRI Evaluation Of Children With Sickle Cell Disease Following Hematopoietic Cell Transplantation,” was published in the journal Biology of Blood and Marrow Transplantation.